Autolus Therapeutics plc AUTL
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Autolus Therapeutics plc (AUTL) is a healthcare company listed in the US with a market value of about $312M. In the twelve months to September 30, 2026 it had revenue of $137M and net income of -$256M, a net margin of -186.4%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -61%.
About Autolus Therapeutics
Autolus Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. It was profitable in 0 of the last 6 years in our data. It spends 156% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $137M | $75M | $10M | $2M | — | — | — |
| Net income | -$256M | -$288M | -$221M | -$208M | -$149M | -$142M | -$142M |
| Free cash flow | -$180M | -$303M | -$228M | -$157M | -$123M | -$127M | -$132M |
| EPS (diluted) | $-0.97 | $-1.08 | $-0.83 | $-0.78 | $-0.56 | $-0.53 | $-0.53 |
| Net margin | -186.4% | -381.4% | -2180.5% | -12272.3% | — | — | — |
| ROIC | — | -85.7% | -39.7% | -109.3% | -35.1% | -33.3% | -54.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $8.36, 615% above the current price; targets range from $5.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.80 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Autolus Therapeutics pay a dividend?
Not currently.
Is Autolus Therapeutics a good stock to buy?
We do not give buy or sell advice. Autolus Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.